Results 181 to 190 of about 27,891 (313)

Differential Impact of Metabolic Bariatric Surgery Versus Semaglutide on Adverse Hepatic and Extrahepatic Outcomes in Individuals With Metabolic Dysfunction‐Associated Steatotic Liver Disease and Type 2 Diabetes

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aim We compared the impact of metabolic bariatric surgery (MBS) versus semaglutide on clinical outcomes in individuals with metabolic dysfunction‐associated steatotic liver disease (MASLD) and type 2 diabetes (T2D). Methods Patients with MASLD and T2D who had MBS or semaglutide in 2018–2023 were identified (TriNetX database).
Weronika Stupalkowska, Alex E. Henney, David R. Riley, Eric G. Sheu, Uazman Alam, Daniel J. Cuthbertson   +5 more
wiley   +1 more source

Semaglutide as a potential tool in pre-lung transplant weight loss optimization. [PDF]

JCEM Case Rep
Ali R, Keyt H, Solis-Herrera C, Escobar-Vasco M.   +3 more
europepmc   +1 more source

Use of Glucagon‐Like Peptide‐1 Receptor Agonists and Risk of Parkinson's Disease: Scandinavian Cohort Study

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims To investigate the association between use of GLP‐1 receptor agonists and incident Parkinson's disease. Material and Methods Cohort study using data from nationwide registers in Denmark, Norway and Sweden and an active‐comparator, new‐user design.
Arvid Engström, Henrik Svanström, Anders Hviid, Björn Eliasson, Soffia Gudbjörnsdottir, Viktor Wintzell, Kristian Hveem, Christian Jonasson, Mads Melbye, Peter Ueda, Björn Pasternak   +10 more
wiley   +1 more source

The ESSENCE of hope: what semaglutide's Food and Drug Administration approval means for metabolic dysfunction-associated steatohepatitis. [PDF]

Hepatobiliary Surg Nutr
Alamgir M, Sohal A, Kowdley KV.
europepmc   +1 more source

Association of Semaglutide Treatment With Liver Cirrhosis and Hepatocellular Carcinoma in Type 2 Diabetes: A Population‐Based Cohort Study

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Background Metabolic dysfunction–associated steatotic liver disease is common among individuals with type 2 diabetes mellitus and substantially increases the risk of liver cirrhosis and hepatocellular carcinoma. Effective therapies that improve metabolic control while preventing advanced liver outcomes are limited.
Assaf Issachar, Talish Razi, Ilya Borochov, Hadar Duskin Bitan, Ronen Arbel   +4 more
wiley   +1 more source

Semaglutide and the Retina

Journal of Diabetes
openaire   +3 more sources

Not All GLP-1 Receptor Agonists Are Alike: Real-World Evidence of Differential Endocrine and Dermatologic Safety. [PDF]

Diabetes Metab Res Rev
Lee N, Kim Y.
europepmc   +1 more source

Efficacy, Safety and PK of Once‐Daily Oral Semaglutide 25 mg for Obesity With and Without Type 2 Diabetes in Comparison With Subcutaneous Semaglutide 2.4 mg: A Model‐Informed Drug Development Approach

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims Semaglutide has previously been approved for weight management and cardiovascular disease as a subcutaneous formulation, and more recently also as an oral formulation. However, there is limited information across oral dose levels, and there are no studies for the 25 mg dose in people with obesity and type 2 diabetes (T2D).
Rune Viig Overgaard, Oscar Birkhan, Naveen Rathor, Thomas Sparsø, Anders Strathe, Sean Wharton, Domenica Rubino   +6 more
wiley   +1 more source

Effects of the glucagon-like peptide-1 receptor agonist liraglutide in juvenile transgenic pigs modeling a pre-diabetic condition [PDF]

, 2015

core   +1 more source

Real-world glycemic control, exploratory cardiorenal indicators, and safety of polyethylene glycol loxenatide versus semaglutide in type 2 diabetes patients: a Chinese two-center retrospective cohort study. [PDF]

Front Endocrinol (Lausanne)
Yu Z, Fu D, Xu J, Lin C, Yin G, Cai, Jiang H, Ling K, Chen J, Zhuo Y.   +9 more
europepmc   +1 more source